About 30 years ago, Goldblatt (1, 2) and von Euler (3, 4) showed that human and ovine seminal plasma contain an acidic lipid (prostaglandin) with vasodepressor activity and smooth muscle-stimulating activity. The early studies have been summarized by von Euler (5, 6). In 1960 Bergstrom and Sjdvall isolated from sheep vesicular glands a highly potent crystalline material, prostaglandin E1 (PGE1) (7).1 The structure of this compound ( Figure 1 ) was established as 2 (6-carboxyhexyl) -3-(3-hydroxyocten-1-yl) -4-hydroxycylopentanone (8) or 11a, 15-dihydroxy-9-ketoprost-13-enoic acid. Further studies showed that two closely related active compounds, PGE2 and PGE3, differing in having one and two additional double bonds, respectively, are also present in sheep vesicular glands (9). Human semen contains approximately equal amounts of these three prostaglandins (10), and PGE1 has been demonstrated in the calf thymus (11). The corresponding compounds in which the keto group of the E compounds has been reduced to an alcohol group (PGFia, PGF2x, and PGF3a) have been isolated in small amounts from seminal plasma, and PGF2a has been isolated from lungs of sheep and pig (12) and from sheep iris (13).
tablished in a variety of other tissues. Whereas the concentrations found are very low, the compounds are extremely potent vasodepressor agents in man and in experimental animals (6, 14) , and a more general physiological function for these unusual compounds remains a possibility.
The present studies show that very low concentrations of PGE1 inhibit glycerol production in adipose tissue and counteract the stimulation of glycerol release induced by catecholamines, glucagon, ACTH, and TSH. This is shown to be due to an interference with the activation of tissue lipase usually produced by exposure of adipose tissue to these hormones. The relative potencies of the several prostaglandins is compared. The vasopressor effects of epinephrine or norepinephrine in dogs are also shown to be blocked by PGE1. A preliminary report of this work has appeared elsewhere (15) .
Methods
The methods and materials used in the in vitro studies have been described in previous papers (16, 17) . Briefly, epididymal fat pads were taken from SpragueDawley rats (150 to 200 g) fed ad libitum until killed by decapitation. Tissues were incubated i hour at 370 C under 95% 02 and 5% C02 in 3 ml Krebs' bicarbonate medium containing bovine serum albumin (30 mg per ml). Glucose was not added to the medium. Glycerol was determined by Korn's modification (18) of the method of Lambert and Neish (19) . FFA were determined by Dole's method (20) , using isooctane in place of heptane.
Tissue phosphorylase was assayed in homogenates prepared at the end of the incubation by methods previously described (21) . Lipase activity in the same homogenates was assayed by methods shown in previous studies to maximize the effects of epinephrine (22, 23 (20) .
The prostaglandin preparations were fully characterized crystalline compounds isolated from sheep prostate glands and, in some cases, chemically modified as described elsewhere (7) (8) (9) . Stock solutions in ethanol were stored at -100 C and diluted in saline or in buffers before use. The final incubation medium contained 0.002% ethanol both in control and experimental flasks. The structure of PGE1 is shown in Figure 1 . PGE2 differs from it only in having an additional double bond in the 5,6 position, whereas PGE3 has additional double bonds at both the 5,6 and the 17,18 positions. The compounds of the F series are analogous to those of the E series except that the 9-keto group has been reduced to a hydroxyl group. The suffixes a and 8 denote the stereoisomeric configuration of this hydroxyl group.
Results
In vitro release of glycerol from fat pad. As shown in Table I PGE2 was also effective in counteracting the epinephrine stimulation of glycerol release, but appeared to be less effective than PGE1 (Table   II) . Because of the considerable variation in response to hormone stimulation observed in tissues from different rats, it is difficult to compare the potency of inhibitors studied in separate experiments. A direct comparison of potencies was made by incubating both fat pads from a single rat with the lipolytic hormone and adding PGE1 to one flask, PGE2 to the other. The results of this direct comparison, shown in Table III, indicated that PGE2 was less potent than PGE1 in antagonizing the action of ACTH and glucagon. The difference in the case of the epinephrine exl)eriments was of borderline significance.
PGE:1 at 0.1 ug per ml did not suppress the action of epinephrine, ACTH, or glutcagon (Table  IT) . At 10 times this concentration, there was still no inhibition in the presence of epinephrine.
A very high concentration of PGE3, 16.6 ,ug per ml, significantly suppressed the activity of epinephrine present at a concentration of 0.1 ,ug per ml. (Table III) . can be compared in Table II . At a concentration
In many of the studies summarized above, FFA of 0.5 ug per ml, PGE2 had a highly significant release into the medium was also measured. The results generally paralleled closely those obtained for glycerol. An important exception was encountered in the studies of the effect of PGE1 in the absence of any added lipolytic hormones. Here there was no significant effect on basal FFA release even though, as shown in Table I , a significant suppression of basal glycerol release could be demonstrated. Changes in tissue lipase and phosphorylase activity. Vaughan has shown that epinephrine and several other lipolytic hormones can activate adipose tissue phosphorylase (21) . These hormones have also been shown to activate lipase system in adipose tissue (22, 23, (25) (26) (27) . With methods described previously (23) , it was shown that the degree of lipase activation induced by epinephrine was decreased by adding PGE1 along with the epinephrine (Table V) . The activation of phosphorylase in these same experiments was also significantly reduced. In these studies, the PGE1 effect was evaluated directly by using paired tissues both of which were exposed to epinephrine. The magnitude of the epinephrine-induced enzyme activation can therefore be estimated only by reference to other similar studies (21, 23) . Such a comparison suggests that the effect on phosphorylase activation was smaller than that on lipase activation.
In vivo studies in anesthetized dogs. Intravenous injection of epinephrine (40 ,ug per kg) into an anesthetized dog caused the expected rise in plasma FFA and blood glucose levels ( Figure  2 of PGE, at the rates shown in Figure 2, sisting for less than 30 seconds, followed by a fall in pressure returning to control values over the course of the next 1 to 2 minutes.
Discussion
The studies reported above show that PGE1 is a remarkably potent antagonist of the fat-mobilizing action of catecholamines in vitro. At 2.8 X 10-7 M concentration, it was highly effective in suppressing the action of norepinephrine present at twice that molar concentration. Significant inhibition was observed at PGE1 concentrations as low as 5.6 X 10-8 M. The lipolytic action of glucagon, ACTH, and TSH was also inhibited. The fact that less than stoichiometric amounts of PGE1 inhibited effectively and the fact that it inhibited the action of these several lipolytic hormones of differing molecular structure suggests that it does not act simply through complex formation with the hormones. The intimate mechanism by which the fat-mobilizing hormones lead to activation of the hormone-sensitive lipase in adipose tissue is not known. The most that can be said is that prostaglandin must interfere at some point in the pathway common to the several hormones whose activity it blocks.
Although the effect of PGE1 on hormone-stimulated activation of phosphorylase appears to be smaller in percentage terms than its effect on lipase activation, this direct quantitative comparison must not be considered definitive, since the absolute magnitude of the hormone-induced increments in enzyme activity, relative to control tissue, was not determined. Preliminary studies with rat liver slices failed to reveal any effect of PGE1 on epinephrine stimulation of glucose release.
Direct comparison of the potency of the different PGE compounds showed that PGE2, although it was active at relatively low concentrations (0.5 to 5.0 Mxg per ml), was less effective than PGE1 in blocking hormone-stimulated lipolysis. PGE3 was without effect at concentrations up to 1 /Ag per ml; at 16.6 pg per ml it significantly reduced epinephrine-stimulated lipolysis. It can be concluded that all three PGE compounds are active, with potencies in the order PGE1 > PGE2 > PGE3.
PGFa and PGF1O, 0.5 ug per ml, did not significantly inhibit epinephrine-stimulated lipolysis. PGFia, 5 Mug per ml, caused some inhibition, but PGF1, was still without effect at this higher concentration. The relative potencies appear to be PGE1 > PGFia > PGF1p. PGF2a was without significant effect at 0.5 Mtg per ml, but was active at a concentration of 5 Mg per ml. Direct comparison confirmed that PGE2 was more potent than its F derivative, PGF2a.
The studies in dogs demonstrate the ability of PGE1 to suppress mobilization of FFA induced by epinephrine in vivo. There was, however, no apparent effect on the degree of hyperglycemia produced by epinephrine. Bergstr6m, Carlson, and Or6 (28) have recently studied the effects of PGE1 in vivo more extensively, making use of constant infusion techniques. Their results confirm the ability of PGE1 to block the FFA-mobilizing action of catecholamines. The availability of these potent inhibitors may be of help in further elucidation of mechanisms controlling fat mobilization. Catecholamines, ACTH, TSH, glucagon. and vasopressin increase the rate of lipolysis in adipose tissue, apparently by favoring the conversion of a specific hormone-sensitive lipase from an inactive to an active form (22, 23, (25) (26) (27) 29) . All of these hormones similarly bring about an increase in phosphorylase activity in adipose tissue. The effects on phosphorylase activity are presumably mediated by cyclic 3',5'-adenosine monophosphate (AMP), but the role of this nucleotide in the lipase system remains to be determined. Cyclic AMP is an intermediate in the effects of vasopressin on permeability of the toad bladder, and it has recently been shown that PGE inhibits the action of vasopressin in that tissue (30) just as it inhibits the effect of vasopressin on lipolysis in adipose tissue (29) .
The potent vasodepressor action of PGE1 was confirmed (6, 14) , and it was further shown that PGE1 sharply reduces the pressor effect of equimolar amounts of epinephrine and of norepinephrine when injected intravenously at the same time as the catecholamines. Since PGE1 alone in the dosages used is strongly vasodepressor, whether it interferes with the hormone-activated mechanism leading to contraction of smooth muscle or whether it simply causes vasodilation by an independent mechanism cannot be decided.
Summary
Prostaglandin E1 (PGE1) at 2.8 x 1Or Ml concentration effectively counteracted the fat-mobilizing activities of epinephrine, norepinephrine, adrenocorticotropic hormone, glucagon, and thyroid-stimulating hormone on the rat epididymal fat pad in vitro, measured in terms of glycerol release into the medium. In the absence of added hormones, the rate of glycerol release from fat pads was slightly decreased by PGE1. PGE1 interfered with the epinephrine-induced activation of a hormone-sensitive lipase in adipose tissue. There was also a small but significant interference with epinephrine-induced activation of phosphorylase.
The relative potencies of a series of closely related compounds in the prostaglandin family as inhibitors of epinephrine-induced fat mobilization in vitro were determined.
The high potency of PGE1 as a vasodepressor agent was confirmed. When injected intravenously into dogs along with approximately equimolar amounts of epinephrine or norepinephrine, PGE1 counteracted the pressor activity of the catecholamines as well as the rise in plasma free fatty acids normally produced. The hyperglycemic response to epinephrine did not appear to be altered.
